ContraFect Corp (CFRX) Stock
CFRX is no longer traded. ContraFect was delisted from the Nasdaq in March 2024.
Prices on this page are historical; the last trade was March 20, 2024 at $0.02.
ContraFect stock price history
CFRX final trading statistics
- Final close
- $0.02
- Final trading day
- Mar 20, 2024
- Market cap at delisting
- $535.2K
- Shares outstanding
- 10.70M
- Final 52-week range
- $0.01 – $3.95
- Avg. volume (final 3 mo.)
- 44,622
- All-time high (split-adj.)
- $1000000.00 · Sep 2014
- All-time low (split-adj.)
- $0.02 · Mar 2024
- Return since IPO
- -100.0%
- Beta
- 0.29
- Book value / share
- -$0.54
- Price / book
- -0.03
ContraFect annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $0.00 | -$24.1M | — |
| FY2022 | $0.00 | -$65.7M | -$112.14 |
| FY2021 | $0.00 | $6.8M | -$44.80 |
| FY2020 | $0.00 | -$28.0M | -$118.40 |
| FY2019 | $0.00 | -$12.6M | -$112.80 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About ContraFect Corp
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. On December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
ContraFect stock FAQ
What happened to ContraFect stock?
ContraFect stock was delisted from the Nasdaq. Its final close was $0.02 on March 20, 2024.
Is CFRX stock still trading?
No. CFRX was delisted from the Nasdaq in March 2024 and no longer trades on a U.S. exchange.
What was the last price of CFRX stock?
CFRX closed at $0.02 on its final trading day, March 20, 2024, for a market value of about $535.2K.
What were ContraFect's revenue and earnings in its last full fiscal year?
ContraFect reported revenue of $0.00 and net income of -$24.1M in fiscal 2023, its last full year as a public company.
When did ContraFect go public?
ContraFect Corp stock began trading on July 29, 2014.